Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Kraig Biocraft Laboratories (KBLB) Consolidated Net Income (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Consolidated Net Income for 10 consecutive years, with -$946847.0 as the latest value for Q4 2022.

  • Quarterly Consolidated Net Income rose 18.67% to -$946847.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$3.8 million through Dec 2022, up 52.25% year-over-year, with the annual reading at -$3.6 million for FY2025, 6.6% down from the prior year.
  • Consolidated Net Income hit -$946847.0 in Q4 2022 for Kraig Biocraft Laboratories, down from -$810356.0 in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$188590.0 in Q2 2018 to a low of -$3.2 million in Q3 2021.
  • Historically, Consolidated Net Income has averaged -$1.0 million across 4 years, with a median of -$940662.0 in 2021.
  • Biggest five-year swings in Consolidated Net Income: skyrocketed 85.03% in 2018 and later plummeted 445.21% in 2019.
  • Year by year, Consolidated Net Income stood at -$494477.0 in 2018, then plummeted by 128.22% to -$1.1 million in 2019, then dropped by 3.17% to -$1.2 million in 2021, then grew by 18.67% to -$946847.0 in 2022.
  • Business Quant data shows Consolidated Net Income for KBLB at -$946847.0 in Q4 2022, -$810356.0 in Q3 2022, and -$1.0 million in Q2 2022.